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ABSTRACT
KIM, J.-S., R. L. WILSON, D. R. TAAFFE, D. A. GALVÃO, E. GRAY, and R. U. NEWTON. Myokine Expression and Tumor-Suppressive
Effect of Serum after 12 wk of Exercise in Prostate Cancer Patients on ADT. Med. Sci. Sports Exerc., Vol. 54, No. 2, pp. 197-205, 2022. Purpose:
Although several mechanisms have been proposed for the tumor-suppressive effect of exercise, little attention has been given to myokines, even
though skeletal muscle is heavily recruited during exercise resulting in myokine surges. We measured resting serum myokine levels before and
after an exercise-based intervention and the effect of this serum on prostate cancer cell growth. Methods: Ten prostate cancer patients undertaking androgen deprivation therapy (age, 73.3 ± 5.6 yr) undertook a 12-wk exercise-based intervention including supervised resistance training,
self-directed aerobic exercise, and protein supplementation. Body composition was assessed by dual-energy x-ray absorptiometry and muscle
strength by the one-repetition maximum method. Fasting blood was collected at baseline and postintervention, and serum levels of myokines
—secreted protein acidic and rich in cysteine, oncostatin M (OSM), decorin, insulin-like growth factor-1, and insulin-like growth factor binding
protein-3 (IGFBP-3)—were measured. The growth of the prostate cancer cell line DU145 with baseline and postintervention serum was measured. Results: Body weight ( P = 0.011), fat mass ( P = 0.012), and percent body fat ( P = 0.033) were reduced, whereas percent lean mass
( P = 0.001) increased, as did strength (leg press, P = 0.006; chest press, P = 0.020) across the intervention. Serum OSM levels ( P = 0.020)
and relative serum OSM levels ( P = 0.020) increased compared with baseline. A significant reduction in DU145 Cell Index ( P = 0.012) and
growth rate ( P = 0.012) was observed after applying postintervention serum compared with baseline serum. Conclusions: This study provides
evidence for enhanced myokine expression and tumor-suppressive effects of serum from chronically exercise-trained prostate cancer patients on
androgen deprivation therapy. Key Words: EXERCISE ONCOLOGY, EXERCISE, MYOKINE, PROSTATE CANCER

E

xercise oncology, the application of exercise medicine
in cancer, has been rapidly evolving in the clinical oncology field and has provided a strong basis for cancer
patients to be engaged in physical activity or exercise (1).
Moreover, epidemiological studies in the field have consistently shown an inverse association between physical activity
and disease progression as well as cancer-specific mortality in
patients, including those with prostate cancer, which is the most
common nonskin cancer in men (2–4). As such, multiple studies have been undertaken to investigate the potential of exercise
in providing benefits for prostate cancer patients, including the
potential direct tumor-suppressive effect of exercise (5).
Among the exercise-induced physiological alterations, systemic alteration of cell-free/soluble content has been suggested
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as a potential mechanism for providing clinical benefits by
retarding prostate cancer growth. Rundqvist and colleagues
(6) demonstrated a 31% reduction in prostate cancer cell line
LNCaP viability with an application of serum acquired after
60 min of aerobic exercise by healthy men compared with serum
acquired before exercise. In addition, a study investigating the effect of serum acquired from healthy subjects after 11 d of intense
exercise plus dietary intervention also demonstrated a 30% reduction of prostate cancer cell line (LNCaP) growth when postintervention serum at rest was applied to prostate cancer cell lines
(7). Similarly, the direct application of serum acquired from active, healthy subjects also reduced prostate cancer cell line
LNCaP growth (27%) compared with sedentary subjects (8).
However, the exercise-conditioned serum samples, both immediately after the exercise bout and resting serum after exercise intervention, were acquired from healthy subjects, and the authors did
not report the effect of potential physiological differences that
prostate cancer patients may experience by disease or treatments,
such as androgen deprivation therapy (ADT).
ADT is an effective therapy for preventing prostate cancer
growth and is a commonly prescribed treatment for prostate
cancer patients at all stages (9). However, prolonged ADT
may promote castrate-resistant prostate cancer (10), which
dramatically reduces patient survival (11). The benefits of exercise for prostate cancer patients undergoing ADT have been
demonstrated in multiple studies investigating the efficacy of
exercise in attenuating treatment toxicities (2,12–14). For instance, we (13,15–18) and others (12,14) have demonstrated
enhancement of physical outcomes such as muscle strength,
lean mass (LM), and physical function, and patient-reported
outcomes such as cancer-related fatigue and quality of life in
these patients as a result of an exercise intervention. However,
no study has investigated the potential of exercise-induced
physiological changes in direct tumor suppression in prostate
cancer patients undergoing ADT.

The role of skeletal muscle as a secretory organ has been
proposed since the early 2000s (19,20). The beneficial roles
of skeletal muscle secretomes called myokines (also known
as exerkines) in muscle hypertrophy and ameliorating metabolic disease have been studied extensively in exercise medicine (19,21–24). Furthermore, preclinical studies that have
applied myokines, such as secreted protein acidic and rich in
cysteine (SPARC) (25–27), oncostatin M (OSM) (28,29),
decorin (30,31), IL-6 (32), IL-15 (33), and irisin (34,35), to
various types of cancer cell lines have also provided evidence
for the potential direct tumor-suppressive role of myokines, including in prostate cancer. However, because of the lack of clinical studies investigating myokine expression among prostate
cancer patients, these myokines are only a candidate molecular
player for tumor suppression (5). Thus, the purposes of the current exploratory study were to investigate the effect of a 12-wk
exercise-based intervention on serum levels of myokines in
prostate cancer patients undertaking ADT and to examine the
growth-suppressive effect of the exercise-conditioned serum.

METHODS
Participants. Recruitment for the study has been previously described (36). Briefly, 54 men with prostate cancer
were contacted initially from February 2018 to June 2019.
The initial contact was made through clinical referral, prostate
cancer support groups, and advertisements and progressed
through the study as shown in Figure 1. The inclusion criteria
were as follows: undertaking ADT for at least 6 months, remaining on ADT for the entire study period, and having a
body fat percentage ≥25%. Patients with bone metastases, a
secondary cancer diagnosis, and musculoskeletal or uncontrolled medical conditions preventing patients from undertaking moderate- to high-intensity exercise were excluded from
the study. As a result, 11 patients completed the intervention

FIGURE 1—CONSORT diagram. BMI, body mass index.
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Neuromuscular strengths for the chest press, leg press, and seated
row exercises were determined using the one-repetition maximum (1RM) method at baseline and postintervention (35).
Each patient’s upper body and lower body relative strength
was also calculated by dividing muscle strength (1RM for
chest press, seated row, and leg press) by the upper body (upper limb LM + trunk LM) or lower body LM (lower limb LM).
Blood assessment and analysis. Resting fasting venous
blood samples (at least 10 h of overnight fasting) were collected
before any physical tests on the day of baseline and postintervention body composition assessments using serum separating tubes.
After blood collection, the blood was left at room temperature for
30 min and then immediately centrifuged at 1600g for 10 min.
The centrifuged blood samples were transported to the Exercise
Medicine Research Institute (Joondalup, WA, Australia), and
the supernatant was carefully aliquoted. The serum samples were
then stored in a −80°C freezer at the Exercise Medicine Research
Institute until further analysis. Serum levels of SPARC, OSM,
IL-6, IL-15, and irisin were analyzed using a multiplexed magnetic bead–based immunoassay (MILLPLEX human myokine
magnetic bead panel; Millipore, Burlington, MA), and serum
levels of decorin, insulin-like growth factor-1 (IGF-1), and
insulin-like growth factor binding protein-3 (IGFBP-3) were
analyzed using an enzyme-linked immunosorbent assay (Human decorin ELISA kit, Human IGF1 SimpleStep ELISA
kit, Human IGFBP-3 SimpleStep ELISA kit; Abcam,
Cambridge, United Kingdom).
Cell culture and real-time cellular analysis. The human prostate cancer cell line, DU145 (ATCC HTB-81), was
obtained from The Harry Perkins Institute, Nedlands, WA,
Australia. DU145 cells were used because they are androgen
insensitive and would minimize the potential effect of androgen
in serum samples. The cells were cultured in RPMI-1640 media

TABLE 1. Changes in physical outcomes and serum myokines levels before and after 12 wk of exercise intervention.
Body composition
Weight (kg)
Total LM (kg)
LM percent (%)
Appendicular LM (kg)
Appendicular LM index (kg·m−2)
Total FM (kg)
FM percent (%)
Body mass index (kg·m−2)
Strength (1RM)
Leg press (kg)*
Chest press (kg)†
Seated row (kg)
Relative strength
Leg press/lower body LM*
Chest press/upper body LM
Seated row/upper body LM*
Serum myokine and growth hormone level
OSM (pg·mL−1)*
SPARC (ng·mL−1)*
Decorin (pg·mL−1)
IGF-1 (pg·mL−1)
IGFBP-3 (pg·mL−1)
IGF-1:IGFBP-3 ratio

Baseline, Mean ± SD

Postintervention, Mean ± SD

P

95.89 ± 13.51
55.97 ± 6.85
58.56 ± 2.77
23.13 ± 3.42
8.01 ± 1.20
37.56 ± 7.40
38.97 ± 3.27
33.15 ± 3.69

92.24 ± 12.74
55.66 ± 6.50
60.58 ± 3.33
23.20 ± 3.33
8.02 ± 1.01
35.01 ± 7.04
37.72 ± 3.21
31.81 ± 3.13

0.011
0.503
0.001
0.817
0.930
0.012
0.033
0.007

84.4 (69.71–115.12)
45.26 ± 13.18
65.02 ± 7.64

96.8 (92.12–144.44)
52.69 ± 13.55
67.52 ± 8.07

0.006
0.020
0.081

5.45 (4.36–6.91)
1.30 ± 0.51
1.75 (1.73–1.97)

6.28 (5.94–8.52)
1.51 ± 0.49
1.91 (1.76–2.13)

0.002
0.027
0.064

3.06 (5.46–7.55)
471.13 (434.15–585.31)
47.91 ± 8.74
975.24 ± 426.04
15827.08 ± 5863.93
0.059 ± 0.020

5.57 (3.80–18.61)
514.96 (583.28–724.10)
49.55 ± 12.56
985.71 ± 613.69
13820.48 ± 5369.70
0.064 ± 0.032

0.020
0.065
0.527
0.774
0.033
0.680

The P < 0.05 is indicated as bold text.
*P values are obtained by the Wilcoxon signed-rank test, and the results are presented as median (interquartile range).
†The result from only nine patients because 1 patient was not able to perform the chest press.
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with data from 10 patients analyzed for this report, as one patient with a very high body mass index (outlier ≥45 kg·m−2)
was excluded. The study was approved by the Edith Cowan
University Human Research Ethics Committee (ID: 18832).
Informed consent was obtained from all subjects involved in
the study before inclusion.
Twelve-week exercise intervention. The 12-wk intervention was designed so that patients accumulated 300 min of
exercise weekly and has been previously described (36).
Briefly, patients undertook three clinic-based supervised resistance exercise sessions per week for 12 wk. The program
was progressive in nature and comprised five to nine resistance exercises targeting the major muscle groups of the upper
and lower body, with one to four sets per exercise at a 6- to 12repetition maximum intensity. Each exercise session was ~1 h
in duration, including a 5- to 10-min aerobic warm-up and
cool-down. The patients were also asked to undertake daily
self-directed moderate to vigorous-intensity aerobic exercise
(rating of perceived exertion, 3–8 on the 0–10 Borg scale). In
addition, patients were provided with two consultations with
an Accredited Practicing Dietician (week 1 and week 3 of intervention) to modify food intake to induce a caloric deficit of
500–1000 kcal·wk−1. To support muscle protein synthesis, patients consumed 40 g of whey protein supplement (Whey Protein Concentrate; Bulk Nutrients, Tasmania, Australia) immediately after each clinic-based exercise session.
Body composition and muscle strength. Body composition was assessed at baseline and postintervention by dualenergy x-ray absorptiometry (Horizon A; Hologic, Washington,
DC). Values derived were whole-body LM (in kilograms), upper
body LM (in kilograms), lower body LM (in kilograms), wholebody fat mass (FM; in kilograms), LM percent, FM percent, and
appendicular LM, which is the sum of upper and lower limb LM.

CLINICAL SCIENCES

containing 10% fetal bovine serum and incubated in a 37°C,
5% CO2 incubator and routinely passaged at ~80% confluence.
The growth of DU145 cells was assessed using a Real-Time
Cellular Analysis system, xCELLigence DP unit (ACEA Bioscience, San Diego, CA), in the presence of human serum.
The xCELLigence DP unit allows for assessment of the cell
number in the unit of the Cell Index in real time by recording
electrical impedance passing through the bottom of the specialized well plates in a specific time frame. Wells were seeded with
15,000 cells onto the E-plate (ACEA Bioscience) with 100 μL
of serum-free RPMI-1640. After 24 h of starvation, 100 μL of
growth media (RPMI-1640) containing 20% human serum (final concentration of 10%) was added to each well of the Eplate. The plates were incubated in the xCELLigence DP unit
for 3 d (72 h) while recording the Cell Index every hour.
Statistical analysis. The data were analyzed using R
software (Version 4.0.2; The R Foundation), with the rstatix
(v0.7.0, Kassambra, 2021) and ggplot2 (v3.3.3, Wickham,
2020) packages for statistics and graphical visualization. All
values are presented as the mean ± SD, with change values presented as the mean and 95% confidence intervals (CI). The

normality of the distribution for outcome measures was tested
using the Shapiro–Wilk test and Q–Q plots. A paired-sample
t-test and Wilcoxon signed-rank test were used, as appropriate,
to investigate the mean difference between baseline and postintervention outcomes, including body composition, physical
outcomes, serum myokine levels, Cell Index at each incubation
time point, and growth rate of the cells. Spearman’s rank-order
correlation was used to investigate the association between
physical outcomes and the serum level of myokines. All tests
were two-tailed, with statistical significance set at P < 0.05.

RESULTS
Body composition and strength. The mean age of the
patients was 73.3 ± 5.6 yr, with an average of 21.2 ± 15.9 months
since ADT was initiated. All patients had a Gleason score ≥7,
with four patients reporting lung or lymph node metastases.
The change in body composition across the 12-wk period was
significant for total body weight (Δtotal body weight = −3.65 kg;
95% CI, −6.22 to −1.09; P = 0.011), percent LM (Δpercent
LM = +2.02%; 95% CI, 1.04 to 2.99; P = 0.001), total FM

FIGURE 2—Graphical illustration of individual data of body composition and strength. A, Whole body weight, total LM, and FM. B, Total LM and FM
percent. C, 1RM strength test of leg press, chest press, and seated row. D, 1RM strength divided by upper or lower body part LM. Lines and dots indicate
individual data, with box-and-whisker representation of the whole group; P values are presented for each comparison. The chest press results were only
available for nine patients.
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decorin, IL-6, IL-15, and irisin) and IGF-1 and IGFBP-3 were
analyzed from serum acquired at baseline and postintervention. However, only OSM, SPARC, decorin, IGF-1, and
IGFBP-3 were able to be analyzed because of the low recovery
of other myokines. The serum levels of IL-6, IL-15, irisin, and
myostatin were not detectable above the threshold using the
commercially available multiplexed magnetic bead–based immunoassay. A significant increase was observed in serum
OSM levels (ΔOSM = + 4.70 ng·mL−1; 95% CI, 0.49 to 8.91;
P = 0.027) and body mass relative OSM levels (serum OMS
levels/total body mass; Δrelative OSM = + 0.06 ng·mL−1·kg−1;
95% CI, 0.01 to 0.10; P = 0.020) before to after the 12-wk intervention (Table 1, Fig. 3). A trend for an increase in serum
SPARC levels was also observed ( P = 0.065), but postintervention
relative SPARC levels (serum SPARC levels/total body mass)
were not changed compared with baseline (Table 1, Fig. 3). Serum
levels of decorin and relative decorin levels did not significantly
change as a result of the intervention (Table 1, Fig. 3). For growth
hormone, serum IGFBP-3 levels were significantly reduced after
the 12-wk intervention (ΔIGFBP-3 = −2006.60 ng·mL−1·kg−1;

FIGURE 3—Serum myokine levels. A, Serum levels of OSM, SPARC, and decorin. B, Relative serum levels of OSM, SPARC, and decorin (serum myokine
levels/total body mass). *Significant changes over a 12-wk exercise intervention. C, Correlation analysis of change values of relative myokine (OSM,
SPARC, and decorin) levels and change values of relative LM over a 12-wk exercise intervention. Lines and dots indicate individual data, with box-andwhisker representation of the whole group; P values are presented for each comparison. Spearman R and P values are indicated for each correlation.
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(Δtotal FM = −2.55 kg; 95% CI, −4.39 to −0.71; P = 0.012),
and percent FM (Δpercent FM = −1.25%; 95% CI, −2.37 to
−0.12; P = 0.033; Table 1, Fig. 2). In contrast, there was no significant change in total LM or appendicular LM. A significant
increase in leg press (Δleg press = +25.84 kg; 95% CI, 6.07
to 45.60; P = 0.006) and chest press (n = 9, Δchest press =
+7.43 kg; 95% CI, 1.53 to 13.34; P = 0.020) muscle strength
was observed after 12-wk training, with a trend for an increase
in seated row strength ( P = 0.081; Table 1, Fig. 2). Relative
strength also increased significantly over the 12-wk intervention when the 1RM for leg press was divided by lower body
LM (Δrelative lower body strength = +1.60; 95% CI, 0.40 to
2.80; P = 0.002) and the 1RM for chest press was divided by
upper body LM (Δrelative upperbody strength = +0.23; 95%
CI, 0.03 to 0.42; P = 0.027; Table 1, Fig. 2). A trend of an increase was also shown in relative upper body strength when
the 1RM for seated row ( P = 0.064) was divided by upper body
LM (Table 1, Fig. 2).
Serum Myokine, IGF-1, and IGFBP-3 levels. Serum
concentrations of six different myokines (SPARC, OSM,

CLINICAL SCIENCES
FIGURE 4—Real-Time Cellular Analysis. A, Time-course changes of DU145 cell growth in the Cell Index after application of serum acquired from prostate
cancer patients undertaking ADT before and after a 12-wk exercise-based intervention (mean ± SD). DU145 cells were starved for 24 h, and growth media
containing 10% serum from baseline and postintervention was applied at time point 0 h. *Significant difference ( P < 0.05). aA strong trend of difference
( P < 0.07) at the same incubation time point. B, Cell Index at 72-h point. C, Average growth rate over 72 h. D, Average growth rate at periods (a) and (b) from
the time-course change of DU145 cell growth. Lines and dots indicate individual data; significance levels are presented. Period (a): 0–24 h; period (b): 25–72 h.

95% CI, −3807.70 to −205.51; P = 0.033); however, serum
IGF-1 and the IGF-1:IGFBP-3 ratio did not significantly change
(Table 1). Furthermore, there was a positive correlation between change of relative OSM levels (ΔOSM serum levels/
Δtotal body mass) and change of relative LM (Δtotal LM/
Δtotal body mass; R = 0.67, P = 0.039), but not for relative
SPARC (ΔSPARC levels/Δtotal body mass) or decorin (Δdecorin
levels/Δtotal body mass) levels with a change of relative LM
(ΔLM/Δtotal body mass (Fig. 3).
Prostate cancer cell line growth. After 24 h of the
starvation period (−23 to 0 h in Fig. 4A), the growth media
containing 10% serum acquired from 10 prostate cancer patients undertaking ADT before and after the 12-wk intervention was applied to the DU145 prostate cancer cell lines and
incubated for 72 h. However, the serum from one participant
was contaminated; therefore, only sera from nine patients were
analyzed. The Cell Index was recorded every 15 min, and the
time-course changes of the Cell Index are presented every hour
in Figure 4. Cell growth presented a particular pattern with
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similar growth during the first 24 h of culture (period (a) in
Fig. 4A) after the addition of the patient’s serum from before
and after the exercise intervention. Curves separate during thereafter (period (b) in Figure 4A). Cell Index at 72 h was significantly
lower for cells cultured with serum acquired after the 12-wk intervention compared with cells treated with baseline serum (Table 1,
Fig. 4B). Overall, the mean Cell Index at 72 h was reduced by
21.3% (baseline: 5.829 ± 1.112, postintervention: 4.566 ± 1.515;
P = 0.012). The average growth rate of the cells over 72 h was significantly reduced by 22.5% (baseline: 0.080 ± 0.016, postintervention: 0.062 ± 0.021; P = 0.012) when the postintervention serum was applied (Fig. 4C). This reduction in cell growth was particularly apparent after 25 h of incubation (Figs. 4A, D),
becoming significantly different after 45 h (Fig. 4A).

DISCUSSION
The aim of this exploratory study was to examine the effect of
a 12-wk exercise-based intervention on potential muscle-induced

http://www.acsm-msse.org
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relative change in LM and serum OSM levels. Our findings are
encouraging, but there is a need for a larger randomized trial to
investigate the effect of exercise on serum myokine levels and
also to examine the threshold exercise intensity/volume required
for chronic myokine adaptations in prostate cancer patients undertaking ADT. Although it was very important to demonstrate
altered myokine levels and tumor suppression from blood collected from trained patients with prostate cancer at rest, the
next logical step is to evaluate the effect of an acute bout of exercise in these patients.
It has been demonstrated from multiple studies that acute or
chronic alteration of cell-free/soluble content might reduce
growth in a range of cancer cells (6–8,44–46). Research by
Rundqvist et al. (6) and Hwang et al. (44) showed the potential
of exercise to directly suppress prostate cancer cell growth by
demonstrating the reduction of LNCaP growth after directly
applying serum acquired after acute exercise. In addition,
these studies also demonstrated alteration in levels of EGF,
IGFBP-1, and the myokines OSM and SPARC. Although
the physiological and cellular response to acute exerciseinduced alteration of cell-free/soluble contents may differ in
prostate cancer patients compared with serum content alteration induced by adaptation to chronic exercise, there is increasing evidence that activated skeletal muscle secretes factors highly influential in tumor suppression. Moreover, the
studies by Barnard et al. (46), Leung et al. (8), and Ngo et al.
(7) reported the potential of the tumor-suppressive effect of
cell-free/soluble components in blood by showing a significant reduction in LNCaP growth and an increase of p53 protein after direct application of serum acquired from a population with regular exercise or after a short, intense exercise–
diet intervention. However, the blood from these studies was
collected from young, healthy subjects, and the studies did
not report the physiological difference between prostate cancer
patients undertaking ADT and the healthy population.
Our examination of the effect of exercise-induced serum
content alteration on prostate cancer cell lines follows the
framework of previous studies (5). As such, we collected serum from patients before and after the 12-wk exercise-based
intervention and applied it directly to the prostate cancer cell
line DU145. The Cell Indexes and growth rates were significantly reduced when serum acquired after the training period
was applied to DU145 cells compared with when preintervention
serum was applied. Our results are in contrast with those of
Dethlefsen et al. (45) and Devin et al. (47), who reported no
tumor-suppressive effect after applying serum acquired from
breast cancer patients and colon cancer survivors, respectively,
to breast and colon cancer cell lines before compared with after
an exercise training intervention. The difference in patient population and cancer cell type in the studies by Dethlefsen et al. (45)
and Devin et al. (47) compared with our study may have resulted
in disparate outcomes. However, outcomes from the studies conducted by Barnard et al. (46), Leung et al. (8), and Ngo et al. (7)
were similar to the current study, indicating serum content alteration via exercise training may have a role in suppressing disease
progression by directly reducing prostate cancer cell growth.
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candidates for tumor suppression in prostate cancer patients undertaking ADT. We confirmed that the exercise program was accompanied by an increase in myokine expression, specifically
OSM, with a change in relative LM positively associated with
myokine expression. Moreover, we examined the effect of serum
conditioned by 12 wk of exercise training on the prostate cancer
cell line DU145. Although we could not signify a direct relationship between muscle-induced myokines and prostate cancer cell
line growth, the postintervention serum drawn from patients in a
rested state significantly reduced DU145 cancer cell growth.
The benefit of exercise for prostate cancer patients undertaking ADT is well established. Hormone suppression has
been shown to result in numerous treatment-related adverse effects and significantly reduces LM and increases FM, especially in the first year of treatment (37). Reduction of LM
and increase in FM can result in sarcopenic obesity, alteration
in cell-free/soluble blood contents, and metabolic imbalance
resulting in poorer disease outcomes (9–11,38,39). However,
in patients with prostate cancer on ADT, exercise has been
shown to enhance body composition and muscle strength,
and improve patient-reported outcomes (13,15–18). Although
the current study was a single group design, our findings confirm the benefits of exercise in improving physical outcomes,
such as body composition and muscle strength of patients undertaking ADT.
The current study is the first to examine myokine expression
before and after an exercise training intervention in prostate
cancer patients undertaking ADT. Although multiple studies
in exercise oncology have investigated the effect of exercise
on the systemic milieu in prostate cancer patients, these
studies only focused on immune markers and adipokines
(40,41). However, it should be noted that, although skeletal
muscle is now recognized as having an extensive endocrine
function and is the organ involved most during exercise, limited studies have explored the role of myokines in direct tumor
suppression (5). In addition, blood was collected after complete rest, that is, no exercise or vigorous exercise within
48 h before blood collection. This was undertaken to eliminate
the acute physical arousal as a result of the last exercise session in order to examine the effect of exercise adaptation on
the systemic milieu in patients with localized prostate cancer.
We sought to examine six different myokines, SPARC,
OSM, decorin, IL-6, IL-15, and irisin, that have previously
been shown in preclinical studies a exert a direct tumorsuppressive effect on cancer cell lines (5). Furthermore, a
higher volume and intensity of exercise was prescribed for
participants in this trial than in previous (42) and current exercise guidelines for cancer patients (43). This might have resulted in a sufficient stimulus for myokine expression in the
circulatory system (5). Although IL-6, IL-15, and irisin were
not able to be analyzed because of the low recovery rate of
the magnetic bead–based immunoassay analysis, we were able
to analyze serum OSM, SPARC, and decorin levels and
showed a significant elevation of serum OSM levels and a trend
for an elevation of serum SPARC levels after the 12-wk intervention. Furthermore, a positive correlation was shown between the
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The current exploratory study has some limitations. Because this was a 12-wk trial, we were unable to examine the
effect of exercise on disease progression or regression in our
patient cohort. Moreover, the program contained a dietary
component aiming to reduce body fat. As such, we can not
conclude that elevations in serum myokines and physical improvements were solely due to exercise training. For instance,
we have also provided the two nutrition consultations and protein supplements throughout intervention; we could not analyze how these dietary components affected the results independently to the exercise, although the previous report from
Wilson et al. (36) have demonstrated no significant changes
in the caloric intakes during a 12-wk weight loss program in
obese prostate cancer patients undertaking ADT. In addition,
although we reported an increase in serum myokine levels
and a significant reduction of DU145 cell growth after applying exercise-conditioned-human serum, the current study is
limited to in-depth intercellular mechanistic measures to signify the tumor-suppressive role of exercise-induced myokines.
Despite these limitations, the current study has strengths
that are worthy of comment. We report the effect of exercise
adaptation after 12 wk of supervised exercise intervention with
dual-energy x-ray absorptiometry used for the whole body and
regional body composition assessment providing accurate
measures of fat and lean tissue. Importantly, the study provided clinically relevant evidence for tumor suppression using
serum acquired from prostate cancer patients undertaking
ADT. The data to date for myokine expression research have
been limited to either healthy cohorts or those with metabolic
disease (5). However, here we report myokine expression in
prostate cancer patients on ADT after exercise training for
the first time, demonstrating that these patients retain the capacity to alter myokine expression through exercise and that
the altered serum contents may be directed to prostate cancer
cell growth suppression.

CONCLUSIONS
The current study provides evidence for enhanced
myokine expression and a resulting tumor-suppressive effect
of exercised-conditioned serum collected at rest in prostate
cancer patients on hormone suppression after a short-term
exercise-based intervention. Importantly, myokine expression
was correlated with the relative change in LM, emphasizing
the importance of maintaining or increasing muscle mass in
these patients. Future randomized controlled trials are needed
to further elucidate the influence of exercise on myokine expression, particularly specifics of exercise prescription such
as threshold exercise intensity, volume, and mode for optimizing myokine expression. Although we have demonstrated
highly beneficial chronic effects of exercise, the acute responses and implications for cancer biology of a single bout
(dose) of exercise in patients with cancer undergoing different
treatments need to be explored. More in-depth intercellular
mechanistic research involving the application of both acute
and chronically exercise-conditioned human serum is also
required to enhance our understanding of the direct tumorsuppressive role of myokines in prostate cancer patients undertaking ADT.
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